Drugs /

pegylated liposomal doxorubicin

Back to Drugs List

Overview

NCI Definition [1]:
A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.

Clinical Trials

View Clinical Trials for pegylated liposomal doxorubicin

Pegylated liposomal doxorubicin has been investigated in 28 clinical trials, of which 24 are open and 4 are closed. Of the trials investigating pegylated liposomal doxorubicin, 7 are phase 1 (5 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (13 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for pegylated liposomal doxorubicin clinical trials.

Fallopian tube carcinoma, ovarian carcinoma, and primary peritoneal carcinoma are the most common diseases being investigated in pegylated liposomal doxorubicin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pegylated Liposomal Doxorubicin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pegylated Liposomal Doxorubicin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pegylated liposomal doxorubicin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pegylated liposomal doxorubicin hydrochloride, liposomal doxorubicin hydrochloride, (8s-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione hydrochloride, doxil, doxorubicin hydrochloride liposomal, doxorubicin hydrochloride liposome, liposomal adriamycin, lipodox, 712227, liposomal doxorubicin hydrochloride, liposomal doxorubicin hydrochloride (substance), doxorubicin hcl liposome, doxorubicin hydrochloride liposome, s-liposomal doxorubicin, doxorubicin hydrochloride (as pegylated liposomal), ati-0918, pegylated liposomal doxorubicin hydrochloride, liposomal doxorubicin hydrochloride, pegylated doxorubicin hcl liposome, (8s-cis)-8-acetyl-10-[(3-amino-2,3,6-trideoxy-a-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione hydrochloride, doxorubicin hydrochloride liposome, dox-sl, pegylated liposomal doxorubicin, liposomal adriamycin, tlc d-99, duomeisu, doxorubicin hydrochloride liposome, duomeisu, liposomal-encapsulated doxorubicin, caelyx, doxorubicin hcl liposome, 31919, doxil, doxorubicin hydrochloride liposome injection, pegylated doxorubicin hcl liposome, stealth liposomal doxorubicin
NCIT ID [1]:
C1555
SNOMED ID [1]:
C-781BD

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.